Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Purdue Pharma Canada

Division of Purdue Pharma LP

Latest From Purdue Pharma Canada

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Purdue Flexes Mid-Sized Muscle

One big drug is dramatically expanding the ambitions of family-owned Purdue. Now the mid-sized firm is aggressively pursuing in-licensing opportunities and building its own research capacity. Its size and private status allow it to craft flexible terms for a broad range of drugs, without worrying about Wall St. But can this inward focused company adapt to the more public requirement of its aggressive growth plans?
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Purdue Frederick Canada
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Purdue Pharma LP
  • Senior Management
  • Craig Landau, MD, Pres. & CEO
    Kelly A Martin, VP, Fin. & CFO
    Julie Ducharme, PhD, VP, R&D
  • Contact Info
  • Purdue Pharma Canada
    Phone: (905) 420-4955
    575 Granite Court
    Pickering, L1W 3W8